Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of GBP 132.44 million. The enterprise value is 90.11 million.

Market Cap	132.44M
Enterprise Value	90.11M

Important Dates

The next estimated earnings date is Wednesday, September 17, 2025.

Earnings Date	Sep 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	92.16M
Shares Outstanding	n/a
Shares Change (YoY)	+0.74%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	59.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	1.44
PS Ratio	7.96
PB Ratio	18.13
P/TBV Ratio	18.13
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.20
EV / Sales	5.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-14.95

Financial Position

The company has a current ratio of 2.60, with a Debt / Equity ratio of 3.51.

Current Ratio	2.60
Quick Ratio	2.50
Debt / Equity	3.51
Debt / EBITDA	n/a
Debt / FCF	-4.25
Interest Coverage	-91.12

Financial Efficiency

Return on equity (ROE) is -162.91% and return on invested capital (ROIC) is -48.98%.

Return on Equity (ROE)	-162.91%
Return on Assets (ROA)	-22.52%
Return on Invested Capital (ROIC)	-48.98%
Return on Capital Employed (ROCE)	-66.06%
Revenue Per Employee	91,931
Profits Per Employee	-226,028
Employee Count	181
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.25% in the last 52 weeks. The beta is 0.98, so Innate Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.98
52-Week Price Change	-16.25%
50-Day Moving Average	1.86
200-Day Moving Average	1.85
Relative Strength Index (RSI)	25.92
Average Volume (20 Days)	4,454

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innate Pharma had revenue of GBP 16.64 million and -40.91 million in losses. Loss per share was -0.50.

Revenue	16.64M
Gross Profit	-26.35M
Operating Income	-42.65M
Pretax Income	-40.91M
Net Income	-40.91M
EBITDA	-41.58M
EBIT	-42.65M
Loss Per Share	-0.50

Full Income Statement

Balance Sheet

The company has 66.79 million in cash and 25.63 million in debt, giving a net cash position of 41.16 million.

Cash & Cash Equivalents	66.79M
Total Debt	25.63M
Net Cash	41.16M
Net Cash Per Share	n/a
Equity (Book Value)	7.31M
Book Value Per Share	0.09
Working Capital	43.63M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.70 million and capital expenditures -323,345, giving a free cash flow of -6.03 million.

Operating Cash Flow	-5.70M
Capital Expenditures	-323,345
Free Cash Flow	-6.03M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -158.34%, with operating and profit margins of -256.32% and -245.87%.

Gross Margin	-158.34%
Operating Margin	-256.32%
Pretax Margin	-245.87%
Profit Margin	-245.87%
EBITDA Margin	-249.86%
EBIT Margin	-256.32%
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.74%
Shareholder Yield	n/a
Earnings Yield	-30.89%
FCF Yield	-4.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -4.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.65
Piotroski F-Score	2